Towa Pharmaceutical Co (4553) Stock Statistics & Valuation Metrics

Towa Pharmaceutical Co has a market cap or net worth of ¥198.09B. The enterprise value is ¥367.02B.

Towa Pharmaceutical Co has 51,516,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Towa Pharmaceutical Co’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 4.12%.

The current PE Ratio of Towa Pharmaceutical Co is 37.7. Towa Pharmaceutical Co’s PEG ratio is -0.52.

In the last 12 months, Towa Pharmaceutical Co had revenue of 259.59B and earned 18.99B in profits. Earnings per share was 385.70.

In the last 12 months, operating cash flow was 28.84B and capital expenditures -29.97B, giving a free cash flow of -1.13B billion.

Towa Pharmaceutical Co pays an annual dividend of ¥40, resulting in a dividend yield of 2.14%

Towa Pharmaceutical Co upcoming earnings date is Aug 6, 2026, TBA (Confirmed).

Towa Pharmaceutical Co as a current ratio of 2.81, with Debt / Equity ratio of ―

In the past 12 months, Towa Pharmaceutical Co has paid 7.34B in taxes.

Towa Pharmaceutical Co EV to EBITDA ratio is 6.60, with an EV/FCF ratio of -59.49.

Towa Pharmaceutical Co has ¥49.58B in cash and marketable securities with ¥226.74B in debt, giving a net cash position of -¥186.69B billion.

Gross margin is ―, with operating margin of 8.95%, and net profit margin of 7.31%.

The average price target for Towa Pharmaceutical Co is ¥5,600.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy